PL3678673T3 - Kompozycje i sposoby do ukierunkowanego dostarczania, ekspresji i modulowania kodujących kwasów rybonukleinowych w tkankach - Google Patents

Kompozycje i sposoby do ukierunkowanego dostarczania, ekspresji i modulowania kodujących kwasów rybonukleinowych w tkankach

Info

Publication number
PL3678673T3
PL3678673T3 PL18792572.2T PL18792572T PL3678673T3 PL 3678673 T3 PL3678673 T3 PL 3678673T3 PL 18792572 T PL18792572 T PL 18792572T PL 3678673 T3 PL3678673 T3 PL 3678673T3
Authority
PL
Poland
Prior art keywords
modulation
tissue
expression
compositions
processes
Prior art date
Application number
PL18792572.2T
Other languages
English (en)
Inventor
Romain MICOL
Slawomir ANTOSZCZYK
Original Assignee
Combined Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combined Therapeutics, Inc. filed Critical Combined Therapeutics, Inc.
Publication of PL3678673T3 publication Critical patent/PL3678673T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL18792572.2T 2017-09-07 2018-09-06 Kompozycje i sposoby do ukierunkowanego dostarczania, ekspresji i modulowania kodujących kwasów rybonukleinowych w tkankach PL3678673T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1714430.4A GB201714430D0 (en) 2017-09-07 2017-09-07 Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
US201862632056P 2018-02-19 2018-02-19
PCT/US2018/049772 WO2019051100A1 (en) 2017-09-07 2018-09-06 COMPOSITIONS AND METHODS FOR TARGETED CODING ADMINISTRATION, EXPRESSION AND MODULATION OF RIBONUCLEIC ACIDS IN TISSUE

Publications (1)

Publication Number Publication Date
PL3678673T3 true PL3678673T3 (pl) 2023-07-10

Family

ID=60117350

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18792572.2T PL3678673T3 (pl) 2017-09-07 2018-09-06 Kompozycje i sposoby do ukierunkowanego dostarczania, ekspresji i modulowania kodujących kwasów rybonukleinowych w tkankach

Country Status (14)

Country Link
US (3) US11359212B2 (pl)
EP (2) EP4218770A3 (pl)
JP (4) JP2020533411A (pl)
KR (1) KR102741572B1 (pl)
CN (1) CN111212650A (pl)
AU (1) AU2018328289B2 (pl)
CA (1) CA3074293A1 (pl)
ES (1) ES2942890T3 (pl)
GB (1) GB201714430D0 (pl)
MX (2) MX2020002568A (pl)
PL (1) PL3678673T3 (pl)
PT (1) PT3678673T (pl)
RU (1) RU2020112990A (pl)
WO (1) WO2019051100A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102776166B1 (ko) 2017-08-07 2025-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 안전한 세포 치료제를 생성하기 위한 플랫폼
GB201714430D0 (en) 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
IL295724A (en) 2020-02-21 2022-10-01 Combined Therapeutics Inc Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
US20240024451A1 (en) 2020-07-31 2024-01-25 Combined Therapeutics, Inc. Compositions and methods for improved vaccination
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
CN113444744A (zh) * 2021-06-28 2021-09-28 北京鼎成肽源生物技术有限公司 一种用于基因编辑NK细胞的mRNA模板及构建方法、mRNA的体外转录方法和应用
CN114107347B (zh) * 2021-11-24 2022-10-28 中国人民解放军空军军医大学 一种基于具有按需抗炎功能、装载炎症响应型mRNA的工程化外泌体及其构建方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024733A2 (en) * 2000-09-15 2002-03-28 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
ES2539941T3 (es) * 2001-05-09 2015-07-07 Takara Bio, Inc. Composición y método para tratar el cáncer usando herpes virus
RU2376371C2 (ru) * 2003-06-18 2009-12-20 Дженелюкс Корпорейшн Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2011101912A1 (ja) * 2010-02-19 2011-08-25 国立大学法人東京大学 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物
JP6113737B2 (ja) * 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) * 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
MX2014010183A (es) 2012-02-22 2015-03-20 Univ Pennsylvania Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
US9597380B2 (en) * 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
AU2014337156A1 (en) * 2013-10-18 2016-05-12 Modernatx, Inc. Compositions and methods for tolerizing cellular systems
ES2810800T3 (es) * 2013-10-28 2021-03-09 Univ Pittsburgh Commonwealth Sys Higher Education Vector de HSV oncolítico
MX2016005915A (es) * 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
JP2017523777A (ja) * 2014-07-17 2017-08-24 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． ポリヌクレオチドの末端修飾
WO2016040395A1 (en) * 2014-09-08 2016-03-17 Massachusetts Institute Of Technology Rna-based logic circuits with rna binding proteins, aptamers and small molecules
WO2016049512A1 (en) * 2014-09-26 2016-03-31 University Of Massachusetts Rna-modulating agents
EP3233132A4 (en) * 2014-12-19 2018-06-27 Modernatx, Inc. Terminal modifications of polynucleotides
WO2017013419A1 (en) * 2015-07-20 2017-01-26 Virttu Biologics Limited Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer
AU2016336344A1 (en) * 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
JP7133468B2 (ja) * 2015-11-20 2022-09-08 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ マイクロｒｎａ認識エレメントを含むｃｍｖベクター
AR107469A1 (es) * 2016-01-27 2018-05-02 Oncorus Inc Vectores virales oncolíticos y sus usos
SG11201903674YA (en) 2016-10-26 2019-05-30 Modernatx Inc Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
GB201714430D0 (en) 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
EP3755344A1 (en) 2018-02-19 2020-12-30 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
IL295724A (en) * 2020-02-21 2022-10-01 Combined Therapeutics Inc Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Also Published As

Publication number Publication date
GB201714430D0 (en) 2017-10-25
KR102741572B1 (ko) 2024-12-10
US11359212B2 (en) 2022-06-14
US20250129383A1 (en) 2025-04-24
US20220220506A1 (en) 2022-07-14
RU2020130763A3 (pl) 2022-03-22
CA3074293A1 (en) 2019-03-14
KR20200104282A (ko) 2020-09-03
ES2942890T3 (es) 2023-06-07
AU2018328289A1 (en) 2020-03-19
US12195746B2 (en) 2025-01-14
EP3678673B1 (en) 2023-01-25
EP3678673A1 (en) 2020-07-15
CN111212650A (zh) 2020-05-29
MX2020008606A (es) 2020-09-21
WO2019051100A1 (en) 2019-03-14
US20200255863A1 (en) 2020-08-13
PT3678673T (pt) 2023-04-24
JP2024059656A (ja) 2024-05-01
MX2020002568A (es) 2020-09-18
RU2020112990A (ru) 2021-10-07
JP2024122983A (ja) 2024-09-10
JP2023159160A (ja) 2023-10-31
RU2020112990A3 (pl) 2022-03-05
RU2020130763A (ru) 2022-03-21
JP2020533411A (ja) 2020-11-19
AU2018328289B2 (en) 2025-07-10
EP4218770A2 (en) 2023-08-02
EP4218770A3 (en) 2023-08-09

Similar Documents

Publication Publication Date Title
PT3678673T (pt) Composições e processos para aministração dirigida, expressão e modulação de ácidos robonucleicos codificantes num tecido
PH12018500719A1 (en) Oligonucleotide compositions and methods thereof
IL287749A (en) Compositions for administering implantable drugs and methods of their use
IL256085B (en) A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
EP3243529A4 (en) Endonuclease targeting blood coagulation factor viii gene and composition for treating hemophilia comprising same
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MX2021001169A (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
EP3173074A4 (en) Composition for delivering bioactive material or protein, and use thereof
IL251503A0 (en) Single-chain biphasic insulin analogs, preparations containing them and their uses
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
MX2019009149A (es) Conjugado de material bioactivo que tiene sustentabilidad mejorada y uso del mismo.
PT3782617T (pt) Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
EP3151923A4 (en) Clear compositions and methods for the delivery of active ingredients for skin care
MY174991A (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
IL247099A0 (en) Beta-converted amino acids and their analogs, preparations containing them and their uses
HUE043758T2 (hu) Hialuronsav vagy annak sója oligomerjének konjugátumai, eljárás azok elõállítására és azok alkalmazása
GB2528421A (en) Methods and processes for application of drug delivery polymeric coatings
ZA201706783B (en) Archaebacteria in bioactive animal feed, method of making the composition and methods employing the composition
IL252683A0 (en) Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses
SG11201610947UA (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
LT3658133T (lt) Kompozicijos, apimančios aminorūgštis, skirtos panaudoti nutukimo gydymui
EP3171858A4 (en) Method and composition for targeted delivery of therapeutic agents